Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Concomitant Alzheimer's disease (AD) pathology is observed in Lewy body diseases (LBD), but the clinical impact is unknown. Only a few biomarker studies in LBD exist and have included small cohorts from single centers. OBJECTIVE: We aimed to evaluate the prevalence of abnormal cerebrospinal fluid (CSF) AD biomarkers across the spectrum of LBD in a large multicenter cohort and to assess whether an AD biomarker profile was associated with demographic and clinical differences in dementia with Lewy bodies (DLB). METHODS: We included 375 DLB patients, 164 Parkinson's disease (PD) patients without dementia, and 55 PD patients with dementia (PDD) from 10 centers. CSF amyloid-beta42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) values were dichotomized as abnormal or normal according to locally available cut-off values. A CSF AD profile was defined as abnormal Aβ42 combined with abnormal t-tau and/or p-tau. RESULTS: A substantial proportion of DLB patients had abnormal values for CSF Aβ42, t-tau, and p-tau, while abnormal values were uncommon in PD without dementia. Patients with PDD had values in between. A CSF AD profile was observed in 25% of DLB patients, compared with only 9% of PDD and 3% of PD without dementia. Within DLB, patients with a CSF AD profile were older, more often female, performed worse on the Mini-Mental State Examination, and had shorter disease duration compared with patients with normal CSF. CONCLUSION: A CSF AD profile is more common in DLB compared with PDD and PD, and is associated with more severe cognitive impairment in DLB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationClinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“…of CSF biomarkers, amyloid-(cid:2) 1–42 (A (cid:2) 42 ), total tau protein (t-tau), and tau phosphorylated at threonine 181 (p-tau) for the diagnosis of AD is clearly established [8], and these markers have been included in the proposed research criteria for the clinical diagnosis of AD [9].”
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationA consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · cited 1×
“In all centers, CSF (1) was obtained by lumbar puncture in the L3-4 or L4-5 interspace; (2) collected in polypropylene tubes and centrifuged for 10 min at 4 ◦ C; and (3) stored in aliquots of 0.5 mL at –80 ◦ C or –70 ◦ C until further analysis [20].”
InfluentialSelf-citationClinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576
Differences in neuropathologic characteristics across the Lewy body dementia spectrum
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E., & Aarsland, D. (2006) · Neurology · doi:10.1212/01.wnl.0000249130.63615.cc · Cited by 335
Self-citationCerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
Schoonenboom, N. S. M., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., Pijnenburg, Y. A. L., Blankenstein, M. A., Rozemuller, A. J., Scheltens, P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31823ed0f0 · Cited by 302
Self-citationCognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273 · cited 1×
“[7, 30–32].”
Cited by
Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143
“In the discovery cohort, Aβ42, Mid-p-tau181, and total-tau were measured using the INNOTEST® β-AMYLOID(1-42), PHOSPHOTAU(181P), and hTAU Ag ELISAs.”
MethodSelf-citationvan Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83
Self-citationFunctional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer’s disease
Habib, M., Mak, E., Gabel, S., Su, L., Williams, G., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.004 · Cited by 53
Metadata
- Authors
- van Steenoven, I., on behalf of the European DLB consortium, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., Kramberger, M. G., Bonanni, L., & Lemstra, A. W.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-08-23
- Volume
- 54
- Issue
- 1
- Pages
- 287-295
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2517746897
- Cited by
- 124
- References
- 10
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. https://app.cochat.ai/papers/10.3233/jad-160322
- The paper
- van Steenoven, I., on behalf of the European DLB consortium, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., Kramberger, M. G., Bonanni, L., & Lemstra, A. W. (2016). Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-160322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.